VIENTIANE, Laos — A GS-441524–based oral antiviral treatment for feline infectious peritonitis (FIP) has received official veterinary approval in the Lao People’s Democratic Republic, marking an important step in expanding regulated treatment options for one of the most serious viral diseases affecting domestic cats.
The approved product is marketed under the brand name NeoFipronis®, with the generic name Pronidesivir. The medicine contains GS-441524, a nucleoside analog antiviral compound that has been widely studied in veterinary medicine for its ability to inhibit replication of the feline coronavirus associated with FIP.
The veterinary approval was granted by the Department of Livestock and Fisheries under the Ministry of Agriculture and Forestry (MAF) of Laos, the national authority responsible for regulating veterinary medicines in the country. With this authorization, NeoFipronis® can now be legally manufactured, distributed, and used as a veterinary treatment for cats diagnosed with feline infectious peritonitis in Laos.
Addressing a Historically Fatal Disease
Feline infectious peritonitis is a progressive viral disease caused by a mutation of feline coronavirus. The disease primarily affects young cats and has historically been associated with a high mortality rate when left untreated.
Over the past decade, advances in antiviral research have demonstrated that GS-441524 can significantly improve outcomes in cats diagnosed with FIP when administered under proper veterinary guidance. Veterinary researchers and clinicians worldwide increasingly recognize antiviral therapy as one of the most effective approaches for managing the disease.
Oral Treatment Designed for Practical Veterinary Use
NeoFipronis® is formulated as a 30 mg GS-441524 oral tablet, offering a convenient treatment option compared with earlier injectable antiviral therapies.
Long-term treatment is typically required for FIP, and oral formulations can help improve treatment compliance for pet owners while reducing the stress associated with repeated injections.
Veterinary professionals note that practical administration methods play an important role in successful FIP management, particularly during extended treatment courses.
Expanding Access to Regulated Antiviral Therapy
The approval of NeoFipronis® in Laos represents an important step toward establishing regulated access to antiviral treatment for FIP. In many regions around the world, GS-441524–based therapies have historically been difficult to access through officially registered veterinary medicines.
By introducing a formally approved product, the Lao regulatory framework provides a pathway for quality-controlled manufacturing, standardized dosing, and responsible veterinary use.
Supporting Veterinarians and Cat Owners
According to the manufacturer, NeoFipronis® (Pronidesivir) is produced under pharmaceutical manufacturing standards and is intended to support veterinarians and cat owners managing cases of feline infectious peritonitis.
Veterinary experts emphasize that early diagnosis and timely antiviral treatment remain critical factors in improving survival outcomes for cats with FIP.
As research into feline coronavirus and antiviral therapies continues to advance, the availability of officially approved veterinary medicines may play an increasingly important role in improving treatment options for cats worldwide.